Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07604896

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab. The study will run over a period of 24 months, with evaluations conducted at baseline, 6 months, and 12 months, 18 months and 24 months. Data from multiple omics layers will be integrated to assess both the efficacy and safety of the treatment.

The primary aim of this study is to assess the efficacy and safety of Lecanemab in patients with Alzheimer's Disease, leveraging multi-omics approaches. Specifically, the study will integrate data from OCT/OCTA imaging of the eye and MRI imaging of the brain, as well as cognitive measures such as ADAS-Cog, MoCA and CDR scores. Furthermore, the presence of ARIA-a significant safety concern in amyloid-targeting therapies-will be closely monitored. The study seeks to provide a more robust understanding of Lecanemab's impact on disease progression, cognition, and potential adverse effects, contributing to a more informed clinical application of this treatment in Alzheimer's care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Alzheimer s Disease Alzheimer Dementia (AD) Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia MCI-AD, Early Stage Alzheimer's Disease Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Location status: Recruiting

Location contact

First Affiliated Hospital of Wenzhou Medical University

CONTACT

[email protected]

+8613858868961

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 50 to 90 years old.
  • No gender restrictions.
  • Patients with MCI and mild AD.
  • The MMSE score is ≥20, and the overall CDR score is 0.5 or 1 point.
  • Positive Amyloid protein confirmed by amyloid-PET or CSF.
  • There is a reliable caregiver accompanying the patient during the research visit and supervising the use of the study drug during the trial.
  • Agree to participate in the research and sign the informed consent form.

Exclusion criteria

  • Patients with cognitive impairment caused by reasons other than AD.
  • There was a history of transient ischemic attack (TIA), stroke, cerebral hemorrhage or epileptic seizure within 12 months prior to screening.
  • A Hamilton Depression Scale score of more than 17 at the time of screening, or any suicidal behavior within 6 months before screening, during screening, or at baseline visits, as well as other psychiatric diagnoses or symptoms (such as hallucinations, anxiety disorders, or delusions) that interfere with the research process of the subjects.
  • Patients with hemorrhagic diseases or those receiving anticoagulant therapy, as well as any patients with malignant tumors, severe gastrointestinal, kidney, liver, respiratory, immune, endocrine and cardiovascular system diseases that affect this study.
  • There is a hypersensitivity reaction to lecanemumab or any other component in the injection solution or any monoclonal antibody treatment.
  • There are contraindications for MRI scans, including the installation of cardiac pacemakers/defibrillators and ferromagnetic metal implants (except for cranial and cardiac devices approved for safe use in MRI scans).
  • There is a known or suspected history of drug or alcohol abuse or dependence within two years prior to screening.
  • Subjects who participated in clinical studies involving any therapeutic monoclonal antibodies or novel compounds for the treatment of AD within 6 months prior to screening, unless it can be demonstrated that the subjects were in the placebo treatment group.
  • Surgical operations under general anesthesia are planned to be performed during the research period.
  • Women who have positive pregnancy test results, are breastfeeding or pregnant at the time of screening or baseline.

Treatment and study plan

Lecanemab 10 mg/kg

Drug

Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.

Conventional anti-dementia treatment group

Drug

Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.

Primary outcomes

  1. Change in Aβ-PET centiloid values

    Time frame: baseline, 12 month, 18 months

    Change in Lecanemab versus Conventional Anti-Dementia Treatment Based on Aβ-PET Centiloid Scores in 18 months

Secondary outcomes

  1. Change of retinal and cerbral imaging

    Time frame: baseline, 6 month, 12 month

    Retinal and cerbral imaging Difference Between Lecanemab and Conventional Anti-Dementia Treatment Groups

  2. Change of MoCA score

    Time frame: baseline, 6 month, 12 month, 18 months

    Assess the difference in MoCA Scores Between Lecanemab and Conventional Anti-Dementia Treatment Groups

  3. Change of MMSE score

    Time frame: baseline, 6 month, 12 month, 18 months

    Assess the difference in MMSE Scores Between Lecanemab and Conventional Anti-Dementia Treatment Groups

  4. Change of CDR score

    Time frame: baseline, 6 month, 12 month, 18 months

    Assess the difference in CDR Scores Between Lecanemab and Conventional Anti-Dementia Treatment Groups

  5. Change of structural MRI

    Time frame: baseline, 6 month, 12 month, 18 month

    3D T1-weighted, 3D T2-weighted and Diffusion Tensor Imaging (DTI)

  6. Change of functional MRI

    Time frame: baseline, 6 month, 12 month, 18 month

    Blood oxygenation level dependent (BOLD) imaging

Study contacts

Contact information is provided by the study sponsor or research team.

Zhen Wang, M.D.

CONTACT

[email protected]

+8613858868961

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Wenzhou Medical University

Other

Registry information

Official study title

Multicenter, Randomized, Controlled Study Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 22, 2026
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.